September 16, 2020 A class action alleges AbbVie, Allergan and Forest Labs conspired to suppress market competition for Bystolic, a blockbuster high blood pressure treatment drug.
December 5, 2019 Another proposed class action claims the maker of now-recalled Biocell textured breast implants failed to warn patients that the product could increase their risk of developing cancer.
October 9, 2019 Allergan faces more potential class action litigation over its recalled Biocell textured breast implants' connection to BIA-ALCL, a cancer of the immune system.
January 17, 2018 Allergan, Inc. has faced a series of lawsuits alleging it unlawfully delayed the entrance to the market of generic alternatives to its cyclosporine ophthalmic emulsion drug, Restasis, causing consumers to be overcharged for the medicine.
January 11, 2018 A proposed class action has been filed in California federal court against Allergan, Inc., claiming the drug manufacturer attempted to delay the entrance of generic alternatives to its cyclosporine ophthalmic emulsion drug, Restasis.
December 12, 2017 Allergan, Inc. is on the receiving end of a proposed class action lawsuit that accuses it of violating antitrust laws with respect to its prescription drug Restasis by attempting to 'extend its monopoly' over the market for cyclosporine emulsion eyedrops.
November 21, 2017 Allergan, Inc. is facing a proposed class action lawsuit that claims it unlawfully attempted to block other companies from competing with it in the market for cyclosporine emulsion drugs.
